Literature DB >> 10545795

Immunohistochemical analysis of midkine expression in human prostate carcinoma.

N Konishi1, M Nakamura, S Nakaoka, Y Hiasa, M Cho, H Uemura, Y Hirao, T Muramatsu, K Kadomatsu.   

Abstract

Midkine (MK) is a growth/differentiation factor frequently expressed at high levels in some types of human malignancies. To investigate whether MK is a useful marker in prostate carcinogenesis, immunohistochemical analysis was performed on samples of both latent and clinical prostate cancers of various stages, as well as on specimens of normal gland and prostatic intraepithelial neoplasia (PIN). Of the 80 clinical cancers examined, 69 specimens (86.3%) were immunoreactive for MK, with metastatic lesions generally showing higher expression than the corresponding primaries; normal prostate tissues were negative or showed only weak staining. Midkine was also detected in 12 of 15 latent cancers (80%) and in 12 of 16 cases of PIN (75%). In sections of whole prostate, MK showed variable expression through tumorous sections, probably in reflection of heterogeneous cell populations. The results demonstrate the possible value of MK as a marker for early and latent disease, as well as for more advanced clinical stages of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545795     DOI: 10.1159/000012039

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  25 in total

1.  The clinical and prognostic significance of midkine in breast cancer patients.

Authors:  Fuguang Li; Peijun Tian; Jun Zhang; Changyuan Kou
Journal:  Tumour Biol       Date:  2015-07-10

Review 2.  Involvement of midkine in neuroblastoma tumourigenesis.

Authors:  S Kishida; K Kadomatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

3.  Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine.

Authors:  Mine Erguven; Ayhan Bilir; Nuray Yazihan; Seval Korkmaz; Esin Aktas; Cem Ovalioglu; Tolga Dundar; Hakan Seyithanoglu
Journal:  Oncol Lett       Date:  2011-10-04       Impact factor: 2.967

4.  H. sinensis mycelium inhibits epithelial-mesenchymal transition by inactivating the midkine pathway in pulmonary fibrosis.

Authors:  Li Lu; Haiyan Zhu; Hailin Wang; Huaping Liang; Yayi Hou; Huan Dou
Journal:  Front Med       Date:  2021-04-27       Impact factor: 4.592

5.  Expression of midkine and its clinical significance in esophageal squamous cell carcinoma.

Authors:  Ying-Jia Ren; Qing-Yun Zhang
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

Review 6.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

7.  Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis.

Authors:  Li-Cheng Dai; Xiang Wang; Xing Yao; Yong-Liang Lu; Jin-Liang Ping; Jian-Fang He
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

8.  In vitro and in vivo suppression of hepatocellular carcinoma growth by midkine-antisense oligonucleotide-loaded nanoparticles.

Authors:  Li-Cheng Dai; Xing Yao; Xiang Wang; Shu-Qiong Niu; Lin-Fu Zhou; Fang-Fang Fu; Shui-Xin Yang; Jin-Liang Ping
Journal:  World J Gastroenterol       Date:  2009-04-28       Impact factor: 5.742

9.  Enhanced therapeutic effects of combined chemotherapeutic drugs and midkine antisense oligonucleotides for hepatocellular carcinoma.

Authors:  Li-Cheng Dai; Xiang Wang; Xing Yao; Yong-Liang Lu; Jin-Liang Ping; Jian-Fang He
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

10.  The advances of Midkine with peripheral invasion in pancreatic cancer.

Authors:  Jun Yao; Wen-Yao Li; She-Gan Gao
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.